Impaired testicular function in patients with carcinoma-in-situ of the testis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Impaired testicular function in patients with carcinoma-in-situ of the testis. / Petersen, P M; Giwercman, A; Hansen, S W; Berthelsen, J G; Daugaard, G; Rørth, M; Skakkebaek, N E.

In: Journal of Clinical Oncology, Vol. 17, No. 1, 1999, p. 173-9.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Petersen, PM, Giwercman, A, Hansen, SW, Berthelsen, JG, Daugaard, G, Rørth, M & Skakkebaek, NE 1999, 'Impaired testicular function in patients with carcinoma-in-situ of the testis', Journal of Clinical Oncology, vol. 17, no. 1, pp. 173-9.

APA

Petersen, P. M., Giwercman, A., Hansen, S. W., Berthelsen, J. G., Daugaard, G., Rørth, M., & Skakkebaek, N. E. (1999). Impaired testicular function in patients with carcinoma-in-situ of the testis. Journal of Clinical Oncology, 17(1), 173-9.

Vancouver

Petersen PM, Giwercman A, Hansen SW, Berthelsen JG, Daugaard G, Rørth M et al. Impaired testicular function in patients with carcinoma-in-situ of the testis. Journal of Clinical Oncology. 1999;17(1):173-9.

Author

Petersen, P M ; Giwercman, A ; Hansen, S W ; Berthelsen, J G ; Daugaard, G ; Rørth, M ; Skakkebaek, N E. / Impaired testicular function in patients with carcinoma-in-situ of the testis. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 1. pp. 173-9.

Bibtex

@article{1ac053e0494411df928f000ea68e967b,
title = "Impaired testicular function in patients with carcinoma-in-situ of the testis",
abstract = "PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis. PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer. RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 x 10(6)/mL and 0.10 x 10(6), respectively) than in patients without (median, 9.1 x 10(6)/mL and 32 x 10(6), respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L). CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.",
author = "Petersen, {P M} and A Giwercman and Hansen, {S W} and Berthelsen, {J G} and G Daugaard and M R{\o}rth and Skakkebaek, {N E}",
note = "Keywords: Adult; Carcinoma in Situ; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Sperm Count; Sperm Motility; Spermatogenesis; Testicular Neoplasms; Testis; Testosterone",
year = "1999",
language = "English",
volume = "17",
pages = "173--9",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

RIS

TY - JOUR

T1 - Impaired testicular function in patients with carcinoma-in-situ of the testis

AU - Petersen, P M

AU - Giwercman, A

AU - Hansen, S W

AU - Berthelsen, J G

AU - Daugaard, G

AU - Rørth, M

AU - Skakkebaek, N E

N1 - Keywords: Adult; Carcinoma in Situ; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Sperm Count; Sperm Motility; Spermatogenesis; Testicular Neoplasms; Testis; Testosterone

PY - 1999

Y1 - 1999

N2 - PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis. PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer. RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 x 10(6)/mL and 0.10 x 10(6), respectively) than in patients without (median, 9.1 x 10(6)/mL and 32 x 10(6), respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L). CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.

AB - PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis. PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer. RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 x 10(6)/mL and 0.10 x 10(6), respectively) than in patients without (median, 9.1 x 10(6)/mL and 32 x 10(6), respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L). CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.

M3 - Journal article

C2 - 10458231

VL - 17

SP - 173

EP - 179

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -

ID: 19279056